Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balinatunfib (SAR441566) in moderate-to-severe rheumatoid arthritis
NCT06073093Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of balinatunfib in rheumatoid arthritis (RA), sponsored by Sanofi. Started Nov 2023; status: completed.
02
Drugs
balinatunfib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06073093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073093.